Bempedoic Acid

證據等級: L5

預測適應症: 10 個

Bempedoic Acid: From Hypercholesterolemia to Homozygous Familial Hypercholesterolemia

One-Sentence Summary

Bempedoic acid is an ATP-citrate lyase (ACLY) inhibitor approved in the US and EU for lowering LDL cholesterol in adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease, though it is not yet marketed in Canada. The TxGNN model generated 10 predicted indications; the most clinically plausible is Homozygous Familial Hypercholesterolemia (HoFH) (model rank 6), supported by 0 registered clinical trials but 17 publications — including a 2026 real-world study confirming adjunctive clinical use in HoFH patients.

Note on TxGNN Rankings: The model’s top five predictions (hyperthyroidism, thyroid hormone receptor-β resistance, malignant catarrh, infectious bovine rhinotracheitis, and CMV infection) are mechanistically implausible or biologically inapplicable to bempedoic acid’s ACLY-inhibiting mechanism; two are exclusively veterinary diseases. HoFH (rank 6, score 99.48%) is the highest-ranked prediction with a direct mechanistic rationale and real-world supporting evidence, and is therefore the focus of this report.

Quick Overview

Item	Content
Original Indication	Hypercholesterolemia — LDL-C reduction in HeFH and established ASCVD (FDA/EMA approved 2020; not approved in Canada)
Predicted New Indication	Homozygous Familial Hypercholesterolemia (HoFH)
TxGNN Prediction Score	99.48% (Rank 6 overall; rank 1 among biologically plausible predictions)
Evidence Level	L3
Canada Market Status	✗ Not marketed
Number of DINs	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Bempedoic acid inhibits ATP-citrate lyase (ACLY), a hepatic enzyme that sits upstream of HMG-CoA reductase in the cholesterol biosynthesis pathway. By reducing the supply of cytosolic acetyl-CoA, it simultaneously curtails both cholesterol and fatty acid synthesis. A critical property of this mechanism is its partial independence from the LDL receptor (LDLR): it reduces hepatic cholesterol output rather than increasing receptor-mediated clearance, making it theoretically active even when LDLR function is impaired.

HoFH arises from biallelic loss-of-function mutations in LDLR (or, less commonly, APOB, PCSK9, or LDLRAP1), resulting in severely elevated LDL-C levels — often exceeding 400 mg/dL — and premature cardiovascular disease in childhood or early adulthood. Because LDLR is non-functional or markedly deficient, therapies that depend on receptor upregulation (statins, PCSK9 inhibitors) provide far less LDL-C reduction in HoFH than in HeFH. Bempedoic acid’s LDLR-independent route therefore offers a plausible, if modest, adjunctive benefit that does not require a functioning receptor.

This mechanistic logic is confirmed in practice: a preclinical large-animal study (PMID 29449335) demonstrated that bempedoic acid lowers LDL-C and attenuates atherosclerosis in LDLR-deficient Yucatan miniature pigs — a well-accepted HoFH surrogate model. A 2026 real-world study (PMID 41274797) then documented its actual clinical use in HoFH patients, typically as add-on therapy to PCSK9 inhibitors and/or evinacumab. Multiple contemporary reviews further position bempedoic acid within the evolving HoFH treatment landscape, acknowledging its limited but real LDLR-independent LDL-C-lowering contribution.

Clinical Trial Evidence

Currently no clinical trials registered for bempedoic acid specifically in homozygous familial hypercholesterolemia.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
41274797	2026	Real-world Study	J Clin Lipidology	First real-world evaluation of bempedoic acid efficacy and tolerability specifically in HoFH patients; confirms adjunctive clinical use
41741298	2026	Expert Consensus	J Clin Lipidology	National Lipid Association consensus update on FH management; addresses bempedoic acid’s role in treatment algorithms
41106315	2025	Narrative Review	Exp Mol Pathol	Comprehensive review of innovative HoFH therapies; bempedoic acid discussed as adjunct for residual LDL-C burden
29449335	2018	Preclinical Study	Arterioscler Thromb Vasc Biol	Bempedoic acid lowers LDL-C and attenuates atherosclerosis in LDLR-deficient (LDLR⁺/⁻ and LDLR⁻/⁻) miniature pigs — key HoFH animal model data
35466160	2022	Narrative Review	J Atherosclerosis Thrombosis	HoFH management review; acknowledges bempedoic acid as an LDLR-independent adjunct in multi-drug regimens
33766264	2021	Review (JACC Focus Seminar)	J Am Coll Cardiology	Positions bempedoic acid among emerging LDL-C-lowering therapies alongside inclisiran and PCSK9i for refractory hypercholesterolemia
34081216	2021	Review	Curr Cardiology Reports	Updates on management of familial and refractory hypercholesterolemias; bempedoic acid reviewed as post-statin option
37071085	2024	Review	Cardiology in Review	Bempedoic acid discussed alongside evinacumab as part of the expanding HoFH treatment arsenal
38576462	2024	Review	Am J Prev Cardiology	Emphasizes cumulative LDL-C exposure as ASCVD driver; bempedoic acid reviewed as adjunctive LDL-lowering strategy
37979722	2024	Review	Indian Heart J	Non-statin lipid-lowering drugs including bempedoic acid for statin-intolerant and refractory patients

Canada Market Information

Bempedoic acid is not currently marketed in Canada (0 DINs on record). For reference, it has been approved in the following jurisdictions under these indications:

Jurisdiction	Brand Name	Approval Year	Approved Indication
United States (FDA)	Nexletol®	2020	Adults with HeFH or established ASCVD requiring additional LDL-C reduction (as adjunct to diet ± other lipid-lowering therapies)
United States (FDA)	Nexlizet® (+ ezetimibe)	2020	Same as above, combination tablet
European Union (EMA)	Nilemdo®	2020	Adults with primary hypercholesterolaemia or mixed dyslipidaemia, as adjunct to diet
European Union (EMA)	Nustendi® (+ ezetimibe)	2020	Same as above, combination tablet

A Health Canada regulatory submission pathway assessment would be required before any Canadian clinical use.

Safety Considerations

Formal Canadian safety data (monograph or TFDA product insert) was not available in this evidence pack. Key safety concerns known from US/EU labelling and clinical literature include:

Hyperuricemia and Gout: Bempedoic acid inhibits urate transporter OAT4, raising serum uric acid; gout flares occurred more frequently than placebo in clinical trials. Caution required in patients with gout history.
Tendon Rupture Risk: Signal observed in clinical trials; patients with tendon disorders or on concomitant fluoroquinolones should be monitored closely.
Pregnancy Contraindication: Animal studies demonstrate embryotoxicity and fetotoxicity. Use during pregnancy is absolutely contraindicated (comparable to Pregnancy Category X). The rank-10 TxGNN prediction for pregnancy-associated osteoporosis must be rejected on this safety ground alone.
Muscle-related Effects: Though bempedoic acid acts upstream of the mevalonate pathway and does not inhibit HMG-CoA reductase directly, a small increase in CPK and rare myopathy reports warrant monitoring, particularly in combination with statins.
Drug Interactions: No DDI data was available in this evidence pack. Known interactions include simvastatin and pravastatin (increased exposure); dose adjustments may be required.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Bempedoic acid’s ACLY-inhibiting, LDLR-independent mechanism is directly relevant to HoFH — a condition in which impaired LDL receptor function limits the efficacy of receptor-dependent standard therapies. A 2026 real-world study confirms it is already being used adjunctively in HoFH, and a preclinical LDLR-deficient large-animal study demonstrates proof-of-concept LDL-C reduction and anti-atherosclerotic effect. Evidence is L3 grade (observational/review-level), which justifies further structured evaluation but not first-line adoption.

To proceed, the following is needed:

A dedicated prospective or randomized study in HoFH patients to quantify the incremental LDL-C reduction that bempedoic acid provides on top of current maximal therapy (PCSK9i ± evinacumab ± lomitapide ± LDL apheresis)
Complete safety monograph review, with specific attention to hyperuricemia, tendon rupture, and embryotoxicity risks
Health Canada regulatory pathway assessment — bempedoic acid is not marketed in Canada; a New Drug Submission (NDS) would be required
Clarification of HoFH genotype-response relationships: patients with residual LDLR activity (missense mutations) may respond differently than those with null mutations
Pharmacoeconomic analysis: given the high cost of existing HoFH therapies and the modest absolute LDL-C reduction expected from ACLY inhibition in an LDLR-null background, cost-effectiveness data will be essential for formulary consideration
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.